The prognosis was poorer in colorectal cancers that expressed both VEGF and PROK1(No correlation coefficient between VEGF and PROK1)

Takanori Goi; Toshiyuki Nakazawa; Yasuo Hirono; Akio Yamaguchi

doi:10.18632/oncotarget.4744

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The prognosis was poorer in colorectal cancers that expressed both VEGF and PROK1(No correlation coefficient between VEGF and PROK1)

Takanori Goi _, Toshiyuki Nakazawa, Yasuo Hirono and Akio Yamaguchi

PDF | HTML | How to cite

Oncotarget. 2015; 6:28790-28799. https://doi.org/10.18632/oncotarget.4744

Metrics: PDF 1470 views | HTML 1752 views | ?

Abstract

Takanori Goi1, Toshiyuki Nakazawa1, Yasuo Hirono1, Akio Yamaguchi1

1First Department of Surgery, University of Fukui, 9101193, Japan

Correspondence to:

Takanori Goi, e-mail: [email protected]

Keywords: colorectal cancer, prokineticin1 (PROK1), vascular endothelial growth factor (VEGF)

Received: May 25, 2015 Accepted: July 17, 2015 Published: July 30, 2015

ABSTRACT

The angiogenic proteins vascular endothelial growth factor (VEGF) and prokineticin1 (PROK1) proteins are considered important in colorectal cancer, the relationship between their simultaneous expression and prognosis was investigated in the present study.

VEGF and PROK1 expression in 620 primary human colorectal cancer lesions was confirmed via immunohistochemical staining with anti-VEGF and anti-PROK1 antibodies, and the correlation between the expression of these 2 proteins and recurrence/prognosis were investigated.

VEGF protein was expressed in 329 (53.1%) and PROK1 protein was expressed in 223 (36.0%). PROK1 and VEGF were simultaneously expressed in 116 (18.7%) of the 620 cases. The correlation coefficient between VEGF expression and PROK1 expression was r = 0.11, and therefore correlation was not observed. Clinical pathology revealed that substantially lymphnode matastasis, hematogenous metastasis, or TMN advanced-stageIV was significantly more prevalent in cases that expressed both VEGF and PROK1 than in the cases negative for both proteins or those positive for only 1 of the proteins.

Also the cases positive for both proteins exhibited the worst recurrence and prognosis. In the Cox proportional hazards model, VEGF and PROK1 expression was an independent prognostic factor.

The prognosis was poorer in colorectal cancers that expressed both PROK1 and VEGF relative to the cases that expressed only 1 protein, and the expression of both proteins was found to be an independent prognostic factor.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4744

Publication Alerts

Research Papers:

The prognosis was poorer in colorectal cancers that expressed both VEGF and PROK1(No correlation coefficient between VEGF and PROK1)

Abstract